The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•15 March 2026•

1 min read

OrbiMed Boosts RAPT Therapeutics Stake Ahead of $58 Per Share Acquisition

Golden image with multiple screens displaying financial dashboards, charts, and circuit board designs. Upward arrows, microchips, and peace symbols are also visible.

Key Facts

1OrbiMed Advisors increased its position in RAPT Therapeutics by 556,273 shares during the fourth quarter.

OrbiMed Advisors significantly increased its position in RAPT Therapeutics during the fourth quarter, according to recent financial reports. The healthcare-focused investment firm added 556,273 shares to its holdings just before the company was acquired. RAPT Therapeutics was subsequently acquired at a price of $58 per share, offering a guaranteed valuation and exit for existing shareholders. Prior to the acquisition, OrbiMed's total stake in the biotechnology firm was valued at approximately $56 million. This institutional accumulation highlights a strategic move by institutional investors ahead of a major corporate event. The acquisition at a premium validates the investment thesis and underscores the ongoing consolidation activity within the biotech sector.